The impact of hypertension on the prognosis of patients with hypertrophic cardiomyopathy: a single-center retrospective study

Background Hypertrophic cardiomyopathy (HCM) and hypertension coexist fairly frequently in clinical practice. However, the evidence about the impact of hypertension on the prognosis of HCM is limited. The present study aims to investigate the impact of hypertension on the prognosis of HCM patients. Methods A total of 468 HCM patients were enrolled, and patients were divided into hypertension group (31.8%) and non-hypertension group (68.2%). The primary study endpoint was HCM-related death, consisting of heart failure (HF)-related death, stroke-related death and sudden cardiac death (SCD). Associations between hypertension and HCM-related death were analyzed by Cox regression models with the use of propensity score matching (PSM) as primary analysis. Results There were 55 HCM-related death during a median follow-up time of 4.6 years, and the mortality rate was 2.53 per 100 person years. Kaplan-Meier analysis based on the crude cohort or PSM cohort revealed no significant difference regarding the HCM-related death between the two groups. In the crude cohort, both univariable and multivariable Cox regression analysis indicated that hypertension was not significantly associated with HCM-related death with hazard ratios (HR) at 0.74 (95% CI [0.40–1.36], p value: 0.329) and 0.77 (95% CI [0.35–1.71], p value: 0.521), respectively. Similarly, no strong evidence for an association was observed between hypertension and HCM-related death in the PSM cohort with unadjusted HR at 0.90 (95% CI [0.34–2.41]; p value: 0.838) and adjusted HR at 0.77 (95% CI [0.35–1.71]; p value: 0.521), respectively. Other propensity score methods, including overlap weighting and inverse probability treatment weighting demonstrated similar results. Sensitivity analysis also indicated that the concomitant hypertension did not significantly increase the risk of HF-related death, stroke-related death or SCD in HCM patients. Conclusion HCM-related death did not significantly differ between hypertension and non-hypertension groups, suggesting a negative impact of hypertension on the clinical prognosis of HCM patients.

[1]  Zhao Liming,et al.  Prognostic nutritional index and the risk of mortality in patients with hypertrophic cardiomyopathy. , 2021, International journal of cardiology.

[2]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[3]  V. Ferreira,et al.  Cardiovascular Magnetic Resonance for the Differentiation of Left Ventricular Hypertrophy , 2020, Current Heart Failure Reports.

[4]  T. Kubo,et al.  Hypertrophic Cardiomyopathy　- A Heterogeneous and Lifelong Disease in the Real World. , 2020, Circulation journal : official journal of the Japanese Circulation Society.

[5]  M. Pencina,et al.  Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial. , 2020, JAMA.

[6]  Jiang He,et al.  The global epidemiology of hypertension , 2020, Nature Reviews Nephrology.

[7]  Bilian Yu,et al.  Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension , 2020, Scientific Reports.

[8]  W. Manning,et al.  Cardiovascular magnetic resonance feature tracking strain analysis for discrimination between hypertensive heart disease and hypertrophic cardiomyopathy , 2019, PloS one.

[9]  S. Srimahachota,et al.  Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand , 2019, BMC Cardiovascular Disorders.

[10]  Y. Adler,et al.  The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy. , 2018, European Heart Journal.

[11]  Tiangang Zhu,et al.  The effect of hypertension on cardiac structure and function in different types of hypertrophic cardiomyopathy: A single-center retrospective study , 2018, Clinical and experimental hypertension.

[12]  A. Wang,et al.  Hypertension and Hypertrophic Cardiomyopathy , 2018, Hypertrophic Cardiomyopathy.

[13]  M. Sabater-Molina,et al.  Genetics of hypertrophic cardiomyopathy: A review of current state , 2018, Clinical genetics.

[14]  E. Braunwald,et al.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. , 2017, Circulation research.

[15]  Wilbert S Aronow,et al.  Hypertension and left ventricular hypertrophy. , 2017, Annals of translational medicine.

[16]  B. Maron,et al.  Perspectives on the Overall Risks of Living With Hypertrophic Cardiomyopathy , 2017, Circulation.

[17]  Peter C. Austin,et al.  Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis , 2016, Statistics in medicine.

[18]  N. Hagiwara,et al.  Stroke and Embolic Events in Hypertrophic Cardiomyopathy: Risk Stratification in Patients Without Atrial Fibrillation , 2016, Stroke.

[19]  F. Rutten,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[20]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[21]  Philippe Van De Borne,et al.  Guidelines for the management of arterial hypertension , 2014 .

[22]  P. Elliott,et al.  Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review , 2013, Heart.

[23]  E. Argulian,et al.  Antihypertensive therapy in hypertrophic cardiomyopathy. , 2013, The American journal of cardiology.

[24]  A. Dawnay,et al.  Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. , 2013, European heart journal.

[25]  W. Manning,et al.  Risk Stratification and Outcome of Patients With Hypertrophic Cardiomyopathy ≥60 Years of Age , 2013, Circulation.

[26]  B. Maron,et al.  Hypertrophic cardiomyopathy , 2013, The Lancet.

[27]  G. Mancia,et al.  Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies , 2012, Journal of Human Hypertension.

[28]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[29]  F. Aslam,et al.  The Frequency and Functional Impact of Overlapping Hypertension on Hypertrophic Cardiomyopathy: A Single‐Center Experience , 2010, Journal of clinical hypertension.

[30]  A. Tajik,et al.  Adverse Prognosis of Patients With Hypertrophic Cardiomyopathy Who Have Epicardial Coronary Artery Disease , 2003, Circulation.

[31]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy with survival to advanced age. , 2003, Journal of the American College of Cardiology.

[32]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[33]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[34]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[35]  J. Laragh,et al.  Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. , 1992, Journal of the American College of Cardiology.